Latest stories on MDNAF
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
StockTitan61 · neutralproduct/pr
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
GlobeNewswire59 · neutralproduct/pr
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
StockTitan59 · neutralproduct/pr
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
Business Insider50 · neutralgeneral
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
Business Insider63 · neutralproduct/pr
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
StockTitan55 · neutralgeneral
Medicenna Therapeutics Corp. GAAP EPS of -$0.06
Seeking Alpha34 · bearishearnings
Medicenna Advances Superkine Pipeline With New Data and Regulatory Plans
TipRanks58 · neutralproduct/pr
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
GlobeNewswire56 · neutralproduct/pr
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights | MDNAF Stock News
StockTitan56 · neutralearnings